ImmunArtes develops a vaccine to block colonization and prevent diseases caused by Staphylococcus aureus and its antibiotic-resistant strains (MRSA). Annually, 3.8M Staph infections occur in the US, incurring $12.4B cost for prevention and treatment. Designed to address the bacteria's immune evasion mechanism, the vaccine demonstrated protection against infection and colonization in mouse models. cGMP manufacturing and pre-clinical study for IND filing are the next steps.